Clinical Trial

A Study of AIR-001 in Adults With Alpha-1 Antitrypsin Deficiency (AATD)

Study acronym: RepAIR1
Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a Phase 1, open-label, single ascending dose (SAD) and multiple dose (MD) study of AIR-001 in participants with alpha-1 antitrypsin deficiency (AATD) due to PiZZ genotype.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2026-02-19; most recent amendment 2026-07-22.
Status change: Not Yet Recruiting → Recruiting 2026-03-09
Trial Details
NCT Number NCT07431112
Lead Sponsor AIRNA Corporation
Conditions Alpha 1 Antitrypsin Deficiency
Enrollment 54 participants
Start Date 2026-03-17
Primary Completion 2028-11 (estimated)
Study Completion 2029-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-24